Posted On: 03/04/2015 10:52:38 AM
Post# of 145202
$DVAX current price just an appetizer. Risk has been dramatically reduced and we will now see more institutional and hedge fund players hesitant build on their current holdings. At present institutional holding close to 80%. O/S 26 million, Market Cap 535 million. Expected Market cap to be before approval over 2 billion
The independent Data and Safety Monitoring Board (DSMB) recommended twice to go ahead with ongoing phase 3 study of HEPLISAV-B(TM). Source: Press release.
This will drive prices much higher! Short term (30-45 days), we may see hitting $30. Watch what happens as each passing month goes buy with no new information from Dynavax. The lack of information is a huge positive as it means that the trial is progressing along just fine as far as safety is concerned.
Phase 3 to release October, 2015
GLTA
The independent Data and Safety Monitoring Board (DSMB) recommended twice to go ahead with ongoing phase 3 study of HEPLISAV-B(TM). Source: Press release.
This will drive prices much higher! Short term (30-45 days), we may see hitting $30. Watch what happens as each passing month goes buy with no new information from Dynavax. The lack of information is a huge positive as it means that the trial is progressing along just fine as far as safety is concerned.
Phase 3 to release October, 2015
GLTA
(0)
(0)
